Albert Collinson, PH.D
Independent Board Member
Dr. Collinson has over 35 years of experience in the pharmaceutical and biotechnology industries. He was the president and Chief Executive Officer at Theracos, Inc. from July 2009-July 2023, a pharmaceutical research and development company focusing on mid- to late- stage assets for the treatment of human diseases including type-2 diabetes. In July 2023, their asset Brenzavvy™ was approved for commercial use. Prior to Theracos Inc., Dr. Collinson founded and served as president and Chief Executive Officer of Opsonic Therapeutics from 2009 to June 2014, a privately held biotechnology company engaged in the development of the next generation of antibody therapeutics. Dr. Collinson also served as the Chief Business Officer of Rib-X Pharmaceuticals from 2004 to 2009, the senior vice president of business development at Phylos, Inc. from 2000 to 2004, and the vice president of global research & development licensing at BASF Pharma from 1998 to 2000. Dr. Collinson began his career as a scientist at ImmunoGen, Inc.